Jess Berry

Yeah, so I think this is one of the most exciting probably spaces in ocular oncology or has been in the past few years.

And a lot of people like Jess Berry, like you mentioned, and Jasmine Francis and the group, you know, both the groups at CHLA in New York and other groups as well, have done amazing work in this space.

I would add in case of retinoblastoma, it's even more of a of an important kind of tool to have because while choroidal melanomas we routinely biopsy with good data on safety and limited seeding cases, very limited or rarely reported seeding cases, we know that for retinoblastoma that is not the case.

And actually one of the big teachings is not to biopsy a retinoblastoma because at that point you might be increasing the risk of extraocular extension.

Those levels drop when you treat the tumor.

I think blood is going to be particularly helpful if you're trying to look at metastatic disease even potentially.

And then finally, to answer your question about safety, the same group from, you know, the Jess Berry's group has published on safety of aqueous sampling.

And they have very good data and there hasn't been any sort of reported seeding.